Thursday, July 9, 2026

pharma · Netherton Syndrome · QNRX

Quoin Pharmaceuticals

Quoin Pharmaceuticals is a pharma organization headquartered in Ashburn, USA. It trades on NYSE under ticker QNRX. Primary therapeutic focus areas include Netherton Syndrome. NovaPharmaNews links 3 clinical program(s), 0

Ashburn, USA HQ
2018 Founded
9 Employees
Public company Type
QNRX · NYSE Ticker
Company details

Quick answer

Quoin Pharmaceuticals is a pharma organization headquartered in Ashburn, USA. It trades on NYSE under ticker QNRX. Primary therapeutic focus areas include Netherton Syndrome. NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (3).

Company snapshot

Founded in 2018, Quoin is an emerging specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities, and care teams. Quoin’s innovative pipeline comprises three products that collectively have the potential to target a broad number of r

  • 3 active pipeline program(s) linked via ClinicalTrials.gov.
  • 3 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Quoin Pharmaceuticals. Not investment advice.

Catalysts

Upcoming readouts, regulatory dates, and congress activity.

  • trial_data

    Japan Grants Orphan Status to QRX003 for Netherton Syndrome: Implications for Pharma Teams

Recent coverage

Top assets

Lead pipeline drugs

Active clinical programs

Momentum

Proprietary activity score for Quoin Pharmaceuticals.

2 active signals

24 /100 +0 vs 30 days ago

Signal breakdown

  • Clinical trials 4 30d
  • Nova articles 1 30d
  • Patents filed 0 30d
  • FDA actions 0 30d
  • SEC filings 0 30d
  • Conference presentations 0 90d
  • Pipeline advances 0 30d

Recent activity

Latest pipeline, patent, and corporate events for Quoin Pharmaceuticals.

  1. Clinical update

    QRX003 — Phase 3

  2. Clinical update

    QRX003, 4% Lotion — Phase 3

  3. Clinical update

    QRX003-2% Lotion — Phase 3

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

  • What is Quoin Pharmaceuticals?

    Quoin Pharmaceuticals is a pharma organization headquartered in Ashburn, USA. It trades on NYSE under ticker QNRX. Primary therapeutic focus areas include Netherton Syndrome. NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from

  • Is Quoin Pharmaceuticals publicly traded?

    Yes. Quoin Pharmaceuticals is listed with ticker QNRX on NYSE per SEC EDGAR records linked on this profile.

  • What drugs does Quoin Pharmaceuticals develop or market?

    No drug profiles are currently linked to Quoin Pharmaceuticals. Pipeline programs may still list investigational assets.

  • What are the latest developments for Quoin Pharmaceuticals?

    In the last 12 months our linked public records show 3 trial program update(s) and 0 US patent grant(s) tied to this profile.

  • What therapeutic areas does Quoin Pharmaceuticals focus on?

    Quoin Pharmaceuticals focuses on Netherton Syndrome based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others
4